JP2002512946A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002512946A5 JP2002512946A5 JP2000545505A JP2000545505A JP2002512946A5 JP 2002512946 A5 JP2002512946 A5 JP 2002512946A5 JP 2000545505 A JP2000545505 A JP 2000545505A JP 2000545505 A JP2000545505 A JP 2000545505A JP 2002512946 A5 JP2002512946 A5 JP 2002512946A5
- Authority
- JP
- Japan
- Prior art keywords
- levosimendan
- controlled release
- composition
- release
- forming polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000013270 controlled release Methods 0.000 description 11
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 description 11
- 229960000692 levosimendan Drugs 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI980901A FI980901A7 (fi) | 1998-04-23 | 1998-04-23 | Levosimendaania säädellysti vapauttavia oraalisia koostumuksia |
| FI980901 | 1998-04-23 | ||
| PCT/FI1999/000329 WO1999055305A2 (en) | 1998-04-23 | 1999-04-23 | Controlled release peroral compositions of levosimendan |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010004367A Division JP2010083900A (ja) | 1998-04-23 | 2010-01-12 | レボシメンダンの制御放出経口用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002512946A JP2002512946A (ja) | 2002-05-08 |
| JP2002512946A5 true JP2002512946A5 (https=) | 2010-03-04 |
| JP4566402B2 JP4566402B2 (ja) | 2010-10-20 |
Family
ID=8551575
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000545505A Expired - Fee Related JP4566402B2 (ja) | 1998-04-23 | 1999-04-23 | レボシメンダンの制御放出経口用組成物 |
| JP2010004367A Withdrawn JP2010083900A (ja) | 1998-04-23 | 2010-01-12 | レボシメンダンの制御放出経口用組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010004367A Withdrawn JP2010083900A (ja) | 1998-04-23 | 2010-01-12 | レボシメンダンの制御放出経口用組成物 |
Country Status (37)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20011465A0 (fi) * | 2001-07-04 | 2001-07-04 | Orion Corp | Pyridatsinonijohdannaisen uusi käyttö |
| WO2004082615A2 (en) * | 2003-03-14 | 2004-09-30 | Nirmal Mulye | A process for preparing sustained release tablets |
| FI20070521L (fi) * | 2006-11-10 | 2008-05-11 | Atacama Labs Oy | Rakeita, tabletteja ja rakeistusmenetelmä |
| MX337213B (es) | 2008-06-30 | 2016-02-17 | Tocagen Inc | Formulaciones de 5-fluorocitosina y usos de las mismas. |
| JP2014172850A (ja) * | 2013-03-07 | 2014-09-22 | Capsugel Belgium Nv | ハードカプセル製剤 |
| CN105784895B (zh) * | 2015-10-30 | 2018-05-22 | 成都欣捷高新技术开发有限公司 | 一种用高效液相色谱仪检测左西孟旦中杂质的方法 |
| WO2021126884A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU555304B2 (en) | 1982-04-05 | 1986-09-18 | Merck Sharp & Dohme Limited | Stabilization of drugs in alginic acid and magnesium hydroxide granules |
| US4716042A (en) | 1986-06-16 | 1987-12-29 | American Home Products Corporation | Stabilized coated aspirin tablets |
| GB8903130D0 (en) | 1989-02-11 | 1989-03-30 | Orion Yhtymae Oy | Substituted pyridazinones |
| GB2251615B (en) * | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
| US5213811A (en) * | 1991-09-13 | 1993-05-25 | Sterling Drug Inc. | Oral sustained-release drug compositions |
| GB2266841A (en) | 1992-05-06 | 1993-11-17 | Orion Yhtymae Oy | Compounds for use as anti-ischemic medicaments |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| GB9614098D0 (en) | 1996-07-05 | 1996-09-04 | Orion Yhtymae Oy | Transdermal delivery of levosimendan |
| FI973804A7 (fi) | 1997-09-26 | 1999-03-27 | Orion Yhtymae Oy | Levosimendaanin oraalisia koostumuksia |
| FI974578L (fi) * | 1997-12-19 | 1999-06-20 | Orion Yhtymae Oyj | Menetelmä levosimendaanin antamiseksi |
| FI980902A7 (fi) * | 1998-04-23 | 1999-10-24 | Orion Yhtymae Oyj | Levosimendaanin stabiileja koostumuksia |
-
1998
- 1998-04-23 FI FI980901A patent/FI980901A7/fi unknown
-
1999
- 1999-03-26 CO CO99018533A patent/CO5070607A1/es unknown
- 1999-04-09 TW TW088105661A patent/TWI224507B/zh not_active IP Right Cessation
- 1999-04-22 AR ARP990101869A patent/AR019096A1/es active IP Right Grant
- 1999-04-23 KR KR1020007011788A patent/KR100960597B1/ko not_active Expired - Fee Related
- 1999-04-23 CN CNB998064181A patent/CN1248691C/zh not_active Expired - Fee Related
- 1999-04-23 HU HU0101458A patent/HUP0101458A3/hu unknown
- 1999-04-23 SI SI9930536T patent/SI1071397T1/xx unknown
- 1999-04-23 JP JP2000545505A patent/JP4566402B2/ja not_active Expired - Fee Related
- 1999-04-23 CZ CZ20003780A patent/CZ295194B6/cs not_active IP Right Cessation
- 1999-04-23 AU AU35246/99A patent/AU756641B2/en not_active Ceased
- 1999-04-23 WO PCT/FI1999/000329 patent/WO1999055305A2/en not_active Ceased
- 1999-04-23 PL PL344078A patent/PL197447B1/pl not_active IP Right Cessation
- 1999-04-23 EP EP99916941A patent/EP1071397B1/en not_active Expired - Lifetime
- 1999-04-23 IL IL13895199A patent/IL138951A0/xx active IP Right Grant
- 1999-04-23 DK DK99916941T patent/DK1071397T3/da active
- 1999-04-23 PT PT99916941T patent/PT1071397E/pt unknown
- 1999-04-23 CA CA002329234A patent/CA2329234C/en not_active Expired - Fee Related
- 1999-04-23 ES ES99916941T patent/ES2215379T3/es not_active Expired - Lifetime
- 1999-04-23 MX MXPA00010367A patent/MXPA00010367A/es unknown
- 1999-04-23 RS YUP-639/00A patent/RS49962B/sr unknown
- 1999-04-23 GE GEAP19995639A patent/GEP20032906B/en unknown
- 1999-04-23 EE EEP200000617A patent/EE04220B1/xx not_active IP Right Cessation
- 1999-04-23 TR TR2000/03102T patent/TR200003102T2/xx unknown
- 1999-04-23 BR BR9909869-5A patent/BR9909869A/pt not_active Application Discontinuation
- 1999-04-23 HR HR20000704A patent/HRP20000704B1/xx not_active IP Right Cessation
- 1999-04-23 US US09/673,794 patent/US7045147B1/en not_active Expired - Fee Related
- 1999-04-23 AT AT99916941T patent/ATE258425T1/de not_active IP Right Cessation
- 1999-04-23 ID IDW20002367A patent/ID27987A/id unknown
- 1999-04-23 UA UA2000116616A patent/UA68376C2/uk unknown
- 1999-04-23 DE DE69914472T patent/DE69914472T2/de not_active Expired - Lifetime
- 1999-04-23 SK SK1554-2000A patent/SK285427B6/sk not_active IP Right Cessation
- 1999-04-23 NZ NZ507453A patent/NZ507453A/xx unknown
- 1999-04-23 EA EA200001098A patent/EA002829B1/ru not_active IP Right Cessation
-
2000
- 2000-10-11 IL IL138951A patent/IL138951A/en not_active IP Right Cessation
- 2000-10-12 ZA ZA200005632A patent/ZA200005632B/en unknown
- 2000-10-20 NO NO20005313A patent/NO329809B1/no not_active IP Right Cessation
- 2000-11-17 BG BG104959A patent/BG64839B1/bg unknown
-
2010
- 2010-01-12 JP JP2010004367A patent/JP2010083900A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2637981B2 (ja) | 吸収制御薬剤組成物 | |
| EP1276469B1 (en) | Taste masking coating composition | |
| EP0067539B1 (en) | Sustained release pharmaceutical composition | |
| US5470584A (en) | Diltiazem formulation | |
| AU760006B2 (en) | Method for making granules with masked taste and instant release of the active particle | |
| EP1276470B1 (en) | Taste masking coating composition | |
| US7771750B2 (en) | Controlled release oral dosage form | |
| US6589553B2 (en) | Controlled release oral dosage form | |
| CN109069480A (zh) | 用于治疗与癫痫相关的病症的方法和组合物 | |
| US10213389B2 (en) | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride | |
| US4859469A (en) | Novel galenic forms of verapamil, their preparation and medicines containing said novel galenic forms | |
| CA2304135C (en) | Medicament formulation with a controlled release of an active agent | |
| KR20100008356A (ko) | 칼슘채널길항제를 포함하는 약제학적 제제 | |
| IE921603A1 (en) | Diltiazem formulation | |
| EP2740471B1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
| JP2002512946A5 (https=) | ||
| US20030035840A1 (en) | Controlled release oral dosage form | |
| GB2098867A (en) | Sustained release pharmaceutical composition | |
| KR20110068985A (ko) | 변형 방출 라미프릴 조성물 및 그것의 사용 | |
| CA2543497A1 (en) | Controlled release analgesic suspensions | |
| NZ249658A (en) | Layered compositions for sustained drug release; preferred drug is porcine somatotropin | |
| JP2004522780A5 (https=) | ||
| EP1539113A2 (en) | Modified release ketoprofen dosage form | |
| CA2685214C (en) | Improved controlled release oral dosage form | |
| WO2006088864A1 (en) | Controlled release compositions comprising levetiracetam |